[
  {
    "ts": "2026-01-16T01:00:00+00:00",
    "headline": "Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs",
    "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plan",
    "url": "https://finance.yahoo.com/news/antengene-presents-jpm-strong-clinical-010000312.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "769b4637-23f1-3f69-a1b8-bd19936f7b28",
      "content": {
        "id": "769b4637-23f1-3f69-a1b8-bd19936f7b28",
        "contentType": "STORY",
        "title": "Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs",
        "description": "",
        "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plan",
        "pubDate": "2026-01-16T01:00:00Z",
        "displayTime": "2026-01-16T01:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583",
          "originalWidth": 400,
          "originalHeight": 170,
          "caption": "Logo (PRNewsfoto/Antengene Corporation Limited)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iX4d3zH6.489mYmi5zPGYg--~B/aD0xNzA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583.cf.webp",
              "width": 400,
              "height": 170,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p3TrWaua._04_VbJue7uzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/antengene-presents-jpm-strong-clinical-010000312.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/antengene-presents-jpm-strong-clinical-010000312.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "6996.HK"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T00:55:49+00:00",
    "headline": "Bioventus Details Turnaround Plan, Four Growth Drivers at J.P. Morgan Conference",
    "summary": "Bioventus (NASDAQ:BVS) executives outlined a multi-year turnaround story and a set of new growth priorities during a presentation and Q&A session hosted by J.P. Morgan healthcare analyst David Brumund. CEO Rob Claypoole and CFO Mark Singleton emphasized recent margin and cash flow improvements,",
    "url": "https://www.marketbeat.com/instant-alerts/bioventus-details-turnaround-plan-four-growth-drivers-at-jp-morgan-conference-2026-01-15/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "29d3fc04-329b-36b3-a8ce-7c153524e359",
      "content": {
        "id": "29d3fc04-329b-36b3-a8ce-7c153524e359",
        "contentType": "STORY",
        "title": "Bioventus Details Turnaround Plan, Four Growth Drivers at J.P. Morgan Conference",
        "description": "",
        "summary": "Bioventus (NASDAQ:BVS) executives outlined a multi-year turnaround story and a set of new growth priorities during a presentation and Q&A session hosted by J.P. Morgan healthcare analyst David Brumund. CEO Rob Claypoole and CFO Mark Singleton emphasized recent margin and cash flow improvements,",
        "pubDate": "2026-01-16T00:55:49Z",
        "displayTime": "2026-01-16T00:55:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/2c5ba8e5cc51cf9a63ff65b609a5c083",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Bioventus logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N259AWQ6U4wqRJyP0RqcBQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/2c5ba8e5cc51cf9a63ff65b609a5c083.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lzg2IRcuf7d3JtHrmAgmSg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/2c5ba8e5cc51cf9a63ff65b609a5c083.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/bioventus-details-turnaround-plan-four-growth-drivers-at-jp-morgan-conference-2026-01-15/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bioventus-details-turnaround-plan-four-005549389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BVS"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T03:15:53+00:00",
    "headline": "Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz",
    "summary": "ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Promising efficacy signals for ORIC-944 in metastatic castration-resistant prostate cancer and a collaboration evaluating enozertinib with Johnson & Johnson’s amivantamab have strengthened confidence in the company’s late-stage cancer pipeline. We’ll now...",
    "url": "https://finance.yahoo.com/news/why-oric-pharmaceuticals-oric-36-031553983.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "bcd9de05-aef9-38cf-b319-2387897ab0ad",
      "content": {
        "id": "bcd9de05-aef9-38cf-b319-2387897ab0ad",
        "contentType": "STORY",
        "title": "Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz",
        "description": "",
        "summary": "ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Promising efficacy signals for ORIC-944 in metastatic castration-resistant prostate cancer and a collaboration evaluating enozertinib with Johnson & Johnson’s amivantamab have strengthened confidence in the company’s late-stage cancer pipeline. We’ll now...",
        "pubDate": "2026-01-16T03:15:53Z",
        "displayTime": "2026-01-16T03:15:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-oric-pharmaceuticals-oric-36-031553983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-oric-pharmaceuticals-oric-36-031553983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ORIC"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T08:07:08+00:00",
    "headline": "Best savings account deals that offer above-inflation rates",
    "summary": "Check the best savings accounts to find a top-rated deal that works for you.",
    "url": "https://uk.finance.yahoo.com/news/best-savings-accounts-deals-inflation-rates-130148742.html",
    "source": "Yahoo Finance UK",
    "provider": "yfinance",
    "raw": {
      "id": "ef17bbd9-c32a-4aa7-a694-2847b774e131",
      "content": {
        "id": "ef17bbd9-c32a-4aa7-a694-2847b774e131",
        "contentType": "STORY",
        "title": "Best savings account deals that offer above-inflation rates",
        "description": "",
        "summary": "Check the best savings accounts to find a top-rated deal that works for you.",
        "pubDate": "2026-01-16T08:07:08Z",
        "displayTime": "2026-01-16T08:07:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-01/c4098550-ed45-11f0-a7e7-fc3b56a64e15",
          "originalWidth": 6016,
          "originalHeight": 4003,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AD0j7nWtdf0wJk_ByGH7GQ--~B/aD00MDAzO3c9NjAxNjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-01/c4098550-ed45-11f0-a7e7-fc3b56a64e15.cf.webp",
              "width": 6016,
              "height": 4003,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8P_RmelKwFT.WRlvG.oB5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-01/c4098550-ed45-11f0-a7e7-fc3b56a64e15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance UK",
          "url": "http://uk.finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/best-savings-accounts-deals-inflation-rates-130148742.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/best-savings-accounts-deals-inflation-rates-130148742.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SAN.MC"
            },
            {
              "symbol": "^FTSE"
            },
            {
              "symbol": "GBPEUR=X"
            },
            {
              "symbol": "GBP=X"
            },
            {
              "symbol": "EUR=X"
            },
            {
              "symbol": "NWG"
            },
            {
              "symbol": "TSCDF"
            },
            {
              "symbol": "TSCDY"
            },
            {
              "symbol": "GBPUSD=X"
            },
            {
              "symbol": "USD=X"
            },
            {
              "symbol": "GBP=X"
            },
            {
              "symbol": "BCS"
            },
            {
              "symbol": "NBS.L"
            },
            {
              "symbol": "SAN"
            },
            {
              "symbol": "GS"
            },
            {
              "symbol": "TSCO.L"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T12:30:43+00:00",
    "headline": "JPM26: Medtech CEO says conference’s appeal in decline",
    "summary": "The limited time to ‘get things done’ and the high cost of attending the J.P. Morgan conference are factors that are beginning to dampen its appeal.",
    "url": "https://www.medicaldevice-network.com/news/jpm26-medtech-ceo-says-conference-appeal-in-decline/",
    "source": "Medical Device Network",
    "provider": "yfinance",
    "raw": {
      "id": "5788a5bb-21d2-3001-8be2-bbf2d99c4acc",
      "content": {
        "id": "5788a5bb-21d2-3001-8be2-bbf2d99c4acc",
        "contentType": "STORY",
        "title": "JPM26: Medtech CEO says conference’s appeal in decline",
        "description": "",
        "summary": "The limited time to ‘get things done’ and the high cost of attending the J.P. Morgan conference are factors that are beginning to dampen its appeal.",
        "pubDate": "2026-01-16T12:30:43Z",
        "displayTime": "2026-01-16T12:30:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medical_device_network_744/078dec82cc049003a1f28c0fb5cbd967",
          "originalWidth": 1440,
          "originalHeight": 960,
          "caption": "According to Dave Rosa",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m07wfKBZwPGeD64_Tse.JA--~B/aD05NjA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medical_device_network_744/078dec82cc049003a1f28c0fb5cbd967.cf.webp",
              "width": 1440,
              "height": 960,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u0sNvhdynbpjph0I5cc00A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medical_device_network_744/078dec82cc049003a1f28c0fb5cbd967.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Medical Device Network",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medicaldevice-network.com/news/jpm26-medtech-ceo-says-conference-appeal-in-decline/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-medtech-ceo-says-conference-123043704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JPM"
            },
            {
              "symbol": "SYK"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T10:30:00+00:00",
    "headline": "Wall Street Is Split on Stock Market’s Top-Performing Sector",
    "summary": "Energy has been the best-performing sector in the S&P 500 Index in the past three months, following crude prices higher as the Trump administration pursued a takeover of Venezuela’s oil industry and threatened to intervene in deadly protests in Iran.  Walter Todd, chief investment officer at Greenwood Capital Associates, said his firm is overweight the sector and sees it as “offering an attractive risk-reward at these levels, particularly versus areas of the market that have already run aggressively over the past year.”",
    "url": "https://finance.yahoo.com/news/wall-street-split-stock-market-103000496.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "23b0f447-4a31-3f49-b328-de8b5f290257",
      "content": {
        "id": "23b0f447-4a31-3f49-b328-de8b5f290257",
        "contentType": "STORY",
        "title": "Wall Street Is Split on Stock Market’s Top-Performing Sector",
        "description": "",
        "summary": "Energy has been the best-performing sector in the S&P 500 Index in the past three months, following crude prices higher as the Trump administration pursued a takeover of Venezuela’s oil industry and threatened to intervene in deadly protests in Iran.  Walter Todd, chief investment officer at Greenwood Capital Associates, said his firm is overweight the sector and sees it as “offering an attractive risk-reward at these levels, particularly versus areas of the market that have already run aggressively over the past year.”",
        "pubDate": "2026-01-16T10:30:00Z",
        "displayTime": "2026-01-16T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/5140efe6db0d9c335ff84aa6e779a96c",
          "originalWidth": 389,
          "originalHeight": 275,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Nwe4AoSwrnxvLFwiYmDhxg--~B/aD0yNzU7dz0zODk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/5140efe6db0d9c335ff84aa6e779a96c.cf.webp",
              "width": 389,
              "height": 275,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wKVb6fZfyvvZH_iGyjnTrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/5140efe6db0d9c335ff84aa6e779a96c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-split-stock-market-103000496.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-split-stock-market-103000496.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "GS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-16T07:22:57+00:00",
    "headline": "The clinical candidates pharma execs are tracking",
    "summary": "Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.",
    "url": "https://www.pharmavoice.com/news/pharma-drug-readout-jpm-merck-summit-takeda-cancer/809807/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "d014d8f9-0bc4-3c6d-a206-5ed55cafe2ea",
      "content": {
        "id": "d014d8f9-0bc4-3c6d-a206-5ed55cafe2ea",
        "contentType": "STORY",
        "title": "The clinical candidates pharma execs are tracking",
        "description": "",
        "summary": "Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.",
        "pubDate": "2026-01-16T07:22:57Z",
        "displayTime": "2026-01-16T07:22:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/943a12d98e3f21d97f1a4fef388ac3b0",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eRkPAe6uzFymkayFLaUg7Q--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/943a12d98e3f21d97f1a4fef388ac3b0.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a7n7Bu00IJTGbJbqcmHK3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/943a12d98e3f21d97f1a4fef388ac3b0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/pharma-drug-readout-jpm-merck-summit-takeda-cancer/809807/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/clinical-candidates-pharma-execs-tracking-072257352.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JPM"
            },
            {
              "symbol": "ONPH"
            },
            {
              "symbol": "ILMN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]